Find a Cancer Provider

Are you a referring physician?
I am searching for a

David L. Porter, MD Physician

Director, Blood and Marrow Transplantation
Jodi Fisher Horowitz Professor in Leukemia Care Excellence

Dr. Porter is a Penn Medicine employed physician.

About Dr. David L. Porter

Recognized annually in Philadelphia Magazine's Top Docs issue from 2004 through 2015

Recognized by America's Top Doctors, 2007, 2008, 2010-2014

Recognized by Best Doctors in America 2009-2010, 2011-2012, 2013-2014

Clinical Specialties


  • Medicine
    • Hematology
    • Medical Oncology

Programs & Centers:

  • Cancer
    • Bone Marrow Transplant and Stem Cell Transplant Program
    • Leukemia Program
    • Lymphoma Program
    • Multiple Myeloma Program
  • Hematology
    • Classical (Non-Malignant) Hematology Program

Board Certification:

  • Hematology, 1994

Clinical Expertise:

  • Allogeneic Transplant
  • Autologous Stell Cell Transplantation
  • Blood Cancer
  • Bone Marrow Transplant
  • Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)
  • Hodgkin Lymphoma
  • Leukemia

Practice Locations and Appointments

Insurance Accepted

  • Aetna US Healthcare
  • Cigna
  • Cigna HealthSpring
  • Devon Health Services (Americare)
  • Gateway Health Plan
  • Geisinger Health Plan
  • HealthAmerica / HealthAssurance, a Coventry Plan
  • HealthPartners
  • HealthSmart
  • Highmark Blue Shield
  • Horizon Blue Cross Blue Shield of New Jersey
  • Humana / Choicecare
  • Independence Blue Cross (Keystone East)
  • Intergroup
  • Keystone First
  • Multiplan
  • NJ Medicaid
  • NJ Qualcare
  • Oxford Health Plan
  • PA Medicaid
  • PA Medicare
  • Preferred Care
  • Rail Road Medicare / Palmetto GBA
  • Tricare
  • United Healthcare
  • UnitedHealthcare Community Plan
  • US Family Health Plan

Education and Training

Medical School: Brown University
Residency: Boston University Hospital
Fellowship: Brigham and Women's Hospital


Advisory Committee, Clinical Cell and Vaccine Production Facility, University of Pennsylvania, Local Advisory Committee, Molecular Diagnostic Core Facility, Local American Board of Internal Medicine, National American Society of Blood and Marrow Transplantation (Member), National American Society of Clinical Oncology (Member), National American Society of Hematology (Member), National American Society of Hematology, National Blood and Marrow Transplant Clinical Trials Network, National Bone Marrow Transplant Clinical Trials Network, Immune Reconstitution Committee, National Center for International Blood and Marrow Transplant Registry, Chronic Leukemia Working Committee., International Center for International Blood and Marrow Transplant Registry, Graft-vs-Host Disease/Immune Reconstitution Working Committee, International Critical Pathways Task Force, Cancer Quality Assurance Committee, University of Pennsylvania Medical Center., Local Data and Safety Monitoring Board, Center for International Blood and Marrow Transplant Research (CIBMTR), Resource for Clinical Investigation in Blood and Marrow Transplantation., International Department of Medicine Clinical Effectiveness and Quality Improvement (CEQI)Committee, University of Pennsylvania Medical Center, Local Genzyme Corporation, National Hematology-Oncology Fellowship Evaluation Committee, Local International Society for Cellular Therapy, International Medical Resource Council, Gilda’s Club, Bucks/Mont Countie, Local National Marrow Donor Program, Donor & Patient Safety Monitoring Committee, National National Marrow Donor Program, National National Marrow Donor Program, National National Marrow Donor Program, National Rhoads 3, 6, 7 Inpatient Hematologic Malignancies and Bone Marrow Transplant Unit, Local Scientific Advisory Committee, Abramson Cancer Center Human Immunology Core, Local Society for Immunotherapy of Cancer, International Society for teh Immunotherapy of Cancer (SITC), National Viropharma, Inc, National Viropharma, National

Hospital Affiliation

Dr. Porter is a Penn Medicine employed physician.

Hospital Privileges:

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.


Selected Publications:

Porter DL, Levine BL, Kalos M, Bagg A, June CH: Delayed tumor lysis and CLL remission from chimeric antigen receptor modified T cells New England Journal of Medicine 365 : 725-733,2011.

Reshef R, Luger S, Hexner EO, Loren AW, Frey NV, Nasta SD, Goldstein SC, Stadmauer EA, Smith J, Bailey S, Mick R, Heitjan DF, Emerson SG, Hoxie JA, Vonderheide RH, Porter DL.: Blockade of Lymphocyte Chemotaxis in Visceral Graft-versus-Host Disease New England Journal of Medicine 367 : 135-145,2012.

Kalos M, Levine BL, Porter DL, Katz S, Grupp SA, Bagg A, June CH.: T cells expressing chimeric receptors establish memory and potent antitumor effects in patients with advanced leukemia Science Translational Medicine 3 : 95ra73,2011.

Anasetti C, Logan BR, Lee SJ, Waller EK, Weisdorf DJ, Wingard JR, Cutler CS, Westervelt P, Woolfrey A, Couban S, Ehninger G, Johnston L, Maziarz RT, Pulsipher MA, Porter DL, Mineishi S, McCarty JM, Khan SP, Anderlini P, Bensinger WI, Leitman SF, Rowley SD, Bredeson C, Carter SL, Horowitz MM, Confer DL.: Peripheral blood stem cells versus bone marrow from unrelated donors: results of Blood and Marrow Transplant Clinical Trials Network protocol 0201, a phase III, prospective, randomized trial. New England Journal of Medicine 367 : 1487-1496,2012.

Porter DL, Alyea EP, Antin JH, DeLima M, Estey, E, Falkenburg JHF, Hardy N, Kroeger N, Leis J, Levine J, Maloney DG, Peggs K, Rowe JM, Wayne AS, Giralt S, Bishop MR, van Besien K.: NCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood and Marrow Transplant 16 : 1467-1503,2010.

Tizon R, Frey N, Heitjan DF, Tan KS, Goldstein SC, Hexner EO, Loren A, Luger SM, Reshef R, Tsai D, Vogl D, Davis J, Vozniak M, Fuchs B, Stadtmauer EA, Porter DL.: High dose corticosteroids with or without etanercept for the treatment of idiopathic pneumonia syndrome after allogeneic SCT. Bone Marrow Transplant 47 : 1332-1337,2011.

Rager A, Frey N, GOldstein SC, Reshef R, Hexner EO, Loren A, Luger SM, Perl, A, Tsai D, Davis J, Vozniak M, Smith J, Stadtmauer EA, Porter DL.: Inflammatory Cytokine Inhibition with Combination Daclizumab and Infliximab for Steroid Refractory Acute Graft-Versus-Host Disease Bone Marrow Transplantation epub : 2010.

Loren AW, Luger SM, Duffy KM, Stadtmauer E, Tsai D, Schuster S, Nasta S, Klumpp T, Orloff G, Porter D.: Alemtuzumab prevents acute graft-vs-host disease (aGVHD) in non-myeloablative stem cell transplants (NST) from unrelated donors. Proc Am Soc Clin Oncol : 2003.

Porter DL, Stadtmauer EA, Lazarus H.: "GVHD": Graft-vs-Host Disease or Graft-vs-Hodgkin's Disease? An Old Acronym with New Meaning. Bone Marrow Transplant 31 : 739-746,2003.

Loren AW, Porter DL: Donor Leukocyte Infusions for the Treatment of Relapsed Acute Leukemia After Allogeneic Stem Cell Transplantation Donor leukocyte infusions for the treatment of relapsed acute leukemia after allogeneic stem cell transplantation. Bone Marrow Transplantation 41 : 483,2007.

Academic Contact Info

3400 Civic Center Boulevard
PCAM 2 West Pavillion

Philadelphia, PA 19104
Phone: (215) 662-2862
Fax: (215) 615-5888
Patient appointments: 800-789-PENN (7366)

Related Links